Limitations, agreements, and source contact

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies · Source last updated 2024-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

point Of Contact

email

maldonado.m@recordati.com

organization

RECORDATIGROUP

phone

+41798030344

title

Mario Maldonado, MD / Head of Clinical Development Global Endocrinology

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice